• 
  Fernanda Mosele, Elise Deluche, Amelie Lusque, Loïc Le Bescond, Thomas Filleron, et al.. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nature Medicine, 2023, 29 (8), pp.2110-2120. ⟨10.1038/s41591-023-02478-2⟩. ⟨hal-04265717⟩
• 
  Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, et al.. Impact of body mass index on overall survival in patients with metastatic breast cancer. Breast, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩. ⟨hal-03345238⟩
• 
  Valentina Mengoli, Ilaria Ceppi, Aurore Sanchez, Elda Cannavo, Swagata Halder, et al.. WRN helicase and mismatch repair complexes independently and synergistically disrupt cruciform DNA structures. EMBO Journal, 2022, 42 (3), ⟨10.15252/embj.2022111998⟩. ⟨hal-04305301⟩
• 
  F. Gauna, S. Carof, E Mouret‐fourme, I. Coupier, V. Mari, et al.. Links between gender norms and the intergenerational transmission of health information in parents carrying BRCA1/2 pathogenic variants. Journal of Genetic Counseling, 2023, Online ahead of print. ⟨10.1002/jgc4.1734⟩. ⟨inserm-04302095⟩
• 
  Sylvain Legrand, Asma Saifudeen, Hélène Bordelet, Julien Vernerey, Arnaud Guille, et al.. Absence of chromosome axis proteins recruitment prevents meiotic recombination chromosome-wide in the budding yeast Lachancea kluyveri. 2023. ⟨hal-04300727⟩
• 
  Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
• 
  Francois Bertucci, Vincent Niziers, Alexandre de Nonneville, Pascal Finetti, Léna Mescam, et al.. Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. Journal for Immunotherapy of Cancer, 2022, 10 (1), pp.e003687. ⟨10.1136/jitc-2021-003687⟩. ⟨hal-03583256⟩
• 
  David Boulate, Marine Fidelle, Caroline Caramella, Justin Issard, Olivier Planche, et al.. Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol. BMJ Open, 2022, 12 (12), ⟨10.1136/bmjopen-2022-067191⟩. ⟨hal-03926501⟩
• 
  Olivier Demaria, Laurent Gauthier, Marie Vetizou, Audrey Blanchard Alvarez, Constance Vagne, et al.. Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. Cell Reports Medicine, 2022, 3 (10), pp.100783. ⟨10.1016/j.xcrm.2022.100783⟩. ⟨hal-03925668⟩
• 
  Sylvain Garciaz, Andrew Guirguis, Sebastian Müller, Fiona Brown, Yih-Chih Chan, et al.. Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. Cancer Discovery, 2022, 12 (3), pp.774-791. ⟨10.1158/2159-8290.CD-21-0522⟩. ⟨hal-03821713⟩
• 
  Jean-Luc Raoul, Marie-Françoise Heymann, Frédéric Dumont, Alain Morel, Hélène Senellart, et al.. Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components. Frontiers in Oncology, 2021, 11, ⟨10.3389/fonc.2021.646992⟩. ⟨hal-03623095⟩
• 
  Sara Berrada, Elena Martínez-Balsalobre, Lise Larcher, Violette Azzoni, Nadia Vasquez, et al.. A clickable melphalan for monitoring DNA interstrand crosslink accumulation and detecting ICL repair defects in Fanconi anemia patient cells. Nucleic Acids Research, 2023, 51 (15), pp.7988 - 8004. ⟨10.1093/nar/gkad559⟩. ⟨hal-04275209⟩
• 
  Carla E Cano, María José Sandí, Tewfik Hamidi, Ezequiel L Calvo, Olivier Turrini, et al.. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer.. EMBO Molecular Medicine, 2012, 4 (9), pp.964-79. ⟨10.1002/emmm.201201255⟩. ⟨hal-01016917⟩
• 
  Lionel Falchero, Florian Guisier, Marie Darrason, Arnaud Boyer, Charles Dayen, et al.. Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study. Lung Cancer, 2023, 185, ⟨10.1016/j.lungcan.2023.107379⟩. ⟨hal-04229547⟩
• 
  Alexandre Bertucci, F. Bertucci, Christophe Zemmour, Florence Lerebours, Jean-Yves Pierga, et al.. PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. Frontiers in Oncology, 2020, 10, ⟨10.3389/fonc.2020.575978⟩. ⟨hal-03623650⟩
• 
  François Bertucci, Anthony Gonçalves, Arnaud Guille, José Adelaïde, Séverine Garnier, et al.. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, 2021, 13 (1), pp.87. ⟨10.1186/s13073-021-00897-9⟩. ⟨hal-03583277⟩
• 
  Véronique Gelsi-Boyer, Virginie Trouplin, José Adélaïde, Nicola Aceto, Virginie Remy, et al.. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes. BMC Cancer, 2008, 8 (1), pp.299. ⟨10.1186/1471-2407-8-299⟩. ⟨hal-03634388⟩
• 
  Mathilde Cancel, Gaelle Fromont, Cyriac Blonz, Christine Chevreau, Nathalie Rioux-Leclercq, et al.. Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales). European Journal of Cancer, 2021, 158, pp.1-11. ⟨10.1016/j.ejca.2021.08.046⟩. ⟨hal-04242387⟩
• 
  Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, et al.. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncology, 2021, 22 (10), pp.1378-1390. ⟨10.1016/S1470-2045(21)00428-9⟩. ⟨hal-03604926⟩
• 
  Raphael J. Morscher, Caroline Brard, Pablo Berlanga, Lynley V. Marshall, Nicolas André, et al.. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial. European Journal of Cancer, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩. ⟨hal-03487880⟩

279

354